Evidence map›Paper›PMID 36057763›Full record

ArticleRheumatology and therapy2022

Febuxostat Therapy for Patients with Gout and Stage 2-4 CKD: a Retrospective Study.

Peiyu Zhang, Mo Chen, Jundi Wang, Shunjie Hu, Xiaoyong Lu, Huaxiang Wu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Rheumatology and therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Peiyu Zhang *Department of Rheumatology, The Second Affiliated Hospital, Zhejiang University School of Medicine, 88 Street, Jiefang Road, Hangzhou, China.
Mo Chen *Department of Rheumatology, The Second Affiliated Hospital, Zhejiang University School of Medicine, 88 Street, Jiefang Road, Hangzhou, China.
Jundi WangAffiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Shunjie HuDepartment of Rheumatology, The Second Affiliated Hospital, Zhejiang University School of Medicine, 88 Street, Jiefang Road, Hangzhou, China.
Xiaoyong LuDepartment of Rheumatology, The Second Affiliated Hospital, Zhejiang University School of Medicine, 88 Street, Jiefang Road, Hangzhou, China. luxyzju18@zju.edu.cn.ORCID http://orcid.org/0000-0002-8975-1999
Huaxiang WuDepartment of Rheumatology, The Second Affiliated Hospital, Zhejiang University School of Medicine, 88 Street, Jiefang Road, Hangzhou, China. wuhx8855@zju.edu.cn.ORCID http://orcid.org/0000-0003-4242-8438
Second Affiliated Hospital of Zhejiang University · CNHangzhou First People's Hospital · CN

Funding

Key Research and Development Program of Zhejiang Province 2020C3044National Natural Science Foundation of China 82071810
6 · The paper itself

Abstract

introductionThe aim of this study is to explore the efficacy and renal safety of febuxostat in gout and stage 2-4 chronic kidney disease (CKD) and factors that correlated with target serum urate (SU).

methodsA single-center retrospective study including male patients with gout and CKD was conducted. SU, the rate of SU < 360 µmol/L (RAT), and renal safety were analyzed in subjects who received febuxostat over 44 weeks. Factors that correlated with target SU were also explored.

resultsBetween January 2017 and March 2021, 102 patients (stage 2 CKD: n = 27; stage 3 CKD: n = 70; stage 4 CKD: n = 5) were enrolled. The SU level reduced significantly over 44 weeks (600.76 ± 95.42 versus 405.52 ± 111.93 µmol/L; P < 0.05), and RAT increased to 39.20%. The overall estimated glomerular filtration rate (eGFR) level improved over 44 weeks (52.05 ± 11.68 versus 55.46 ± 14.49 mL/min/1.73 cm

conclusionsFebuxostat demonstrated efficacy and renal safety in patients with gout and CKD in clinical practice. Achieving the target SU could obviously improve renal function. Baseline SU level and body weight could affect the achievement of target SU.

Indexed as

Chronic kidney diseaseFebuxostatGoutRenal safetyTarget serum urate

Identifiers

PMID36057763
PMCPMC9510076
OpenAlexW4294531099

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.